http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008070885-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02fd02fa43c6382407492b9fbc8725fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34c5860d3c705116209c28954cf81415 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D273-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D291-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D281-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D245-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D291-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D273-02 |
| filingDate | 2007-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f5f4453e44ae00ac9819aa347912dba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8314781a08ca0d789d316d93b57c2c8f |
| publicationDate | 2008-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2008070885-A1 |
| titleOfInvention | Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof |
| abstract | The present invention relates to macro-cyclic compounds of formula (I), wherein R 1 , is (C 1-8 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, hydroxy(C 1-6 )alkyl, (C 1-4 )alkylthio(C 1-4 )alkyl, (C 1-6 )alkenyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, piperidinyl or pyrrolidinyl, R 2 and R 4 , independently, are hydrogen or optionally substituted (C 1-8 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-4 )alkyl, aryl, aryl(C 1-4 )alkyl, heteroaryl or heteroaryl(C 1-4 )alkyl, or R 2 and R 4 , together with the nitrogen to which they are attached, form an optionally substituted piperidino, pyrrolidinyl, morpholino or piperazinyl group, R 3 is hydrogen or (C 1-4 )alkyl, X 1 is CH 2 , X 2 is CH 2 , O, S, CO, COO, OCO, NHCO, CONH, or NR, R being hydrogen or (C 1-4 )alkyl, Y is (C 1-8 )alkylen or (C 1-8 )alkylenoxy(C 1-6 )alkylen, (C 1-8 )alkenylen or (C 1-8 )alkenylenoxy(C 1-6 )alkylen, Ar is a phenyl ring optionally mono- di or trisubstituted by, independently, hydroxy or halogen, whereby X 1 , and X 2 are in meta or para position to each other, and either Z is CO, AA is a natural or unnatural alpha-amino-acid, and n is 0 or 1, or Z is S0 2 , AA is an optionally substituted ethylencarbonyl group (derived from a natural or unnatural alpha-amino acid by replacement of the nitrogen by a methylen group), and n is 1; processes for the preparation of these compounds; pharmaceutical compositions and combinations comprising the same; and their use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation. |
| priorityDate | 2003-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 528.